Technologies on display included intravascular lithotripsy (IVL) systems, transcatheter heart valves, renal denervation (RDN) technologies, drug-eluting stents and more.
Usual big names in the cardiovascular space like Medtronic, Boston Scientific and Abbott shared updates. Meanwhile, innovators like Jupiter Neurovascular, Elixir Medical and more provided their own clinical findings supporting their technologies, too.
Many of these companies also made their presence felt at EuroPCR 2025. Read the top news from that edition here.
A year on, here are the biggest stories out of EuroPCR 2026:
Boston Scientific study of Seismiq coronary IVL meets endpoints
The pivotal FDA investigational device exemption (IDE) trial evaluated the use of the Seismiq 4CE coronary IVL catheter in the treatment of patients with severely calcified coronary artery disease (CAD).
Marlborough, Massachusetts–based Boston Scientific said the study met its primary safety and efficacy endpoints. Seismiq demonstrated high rates of freedom from major adverse cardiac events (MACE) at 30 days, plus procedural success.
Medtronic studies back TAVR, RDN systems
SMART (SMall Annuli Randomized To) Evolut or Sapien is the largest head-to-head comparative trial of transcatheter aortic valve replacement (TAVR).
Medtronic says the study evaluated patients with aortic stenosis (AS) and a small aortic annulus. Results demonstrated that all individual and composite hemodynamic measures continue to be superior at three years for Evolut TAVR compared to Sapien, according to the medtech giant.
Symplicity Spyral delivers radiofrequency energy to nerves near the kidneys in a minimally invasive procedure to treat hypertension. These nerves can become overactive and contribute to high blood pressure. The RDN system holds approval for commercial use in more than 80 countries.
Medtronic shared two separate analyses, both highlighting durable, effective treatment with the Symplicity system.
Abbott study findings back Navitor TAVI system
Navitor currently has U.S. approval to treat symptomatic severe aortic stenosis in those at high or extreme risk for open-heart surgery. This includes patients with considerations related to age, frailty, or other health conditions. Abbott said its TAVI system represents a viable and less invasive option for this patient population.
Abbott launched the latest generation of the valve in 2024, then won expanded CE mark approval in August 2025.
Philips introduces SmartIQ imaging tech for Azurion image-guided therapy
Amsterdam-based Philips developed the technology in collaboration with leading cardiovascular centers. It designed SmartIQ to address the trade-off between image quality and radiation exposure for patients and clinical staff.
According to Philips, SmartIQ enables clinicians to see what they need with exceptional quality while providing reassurance that X-ray dose and contrast levels are optimized.
The company says SmartIQ marks a step forward in image quality and dose management in coronary imaging. It includes an ultra-low dose protocol for coronary procedures that employs over 50% less X-ray radiation dose compared with the lowest dose settings available with Philips ClarityIQ.
Elixir Medical study backs DynamX bioadaptor against drug-eluting stent
The BIOADAPTOR randomized controlled trial compared DynamX to the Medtronic Resolute Onyx DES, the current standard of care. It compared the therapies across Japan, Europe and New Zealand. Investigators shared findings from 445 patients in Paris.
Elixir said the four-year results highlight durable clinical outcomes with DynamX. Investigators reported no new target lesion failure (TLF) or cardiovascular death (CVD) events between years three and four. The system maintained a very low plateauing rate of adverse events, compared to a continued annual increase with DES.
Elixir Medical’s sirolimus-eluting DynamX bioadaptor features a novel design and mechanism of action designed to return the diseased vessel to a more normal condition. It works in three distinct phases.
Jupiter Endovascular reports positive findings for Vertex pulmonary embolectomy system
SPIRARE II evaluates the Vertex system in patients with acute, intermediate-risk pulmonary embolism (PE). Menlo Park, California-based Jupiter completed enrollment in the trial in February. The company said today that the study met both primary endpoints, demonstrating meaningful heart recovery and clinical safety.
Vertex incorporates Jupiter’s novel transforming fixation (TFX) technology into an endovascular procedure. It designed the technology to treat acute pulmonary embolism (PE) with control and precision.
The system delivery takes place in a flexible, relaxed state over a guidewire to a target location in the vasculature. Rapidly pressurized with saline, it fixes in a stable position for intervention. Then, it returns to a relaxed state to navigate to another target location or for removal.
Reflow Medical has positive data for coronary drug-eluting stent
San Clemente, California-based Reflow designed its stent system to transfer a proprietary drug formulation to the diseased lesion without leaving a permanent metallic implant behind. The device’s retrievable scaffold therapy creates channels to increase the uptake of antiproliferative drugs. Meanwhile, it dilates the arterial lumen to maximize gain during the procedure. Doctors then remove the device without leaving anything behind.
Reflow describes the stent as the first and only retrievable self-expanding stent with radially expandable spikes integrated with a balloon. Both have a drug coating with a unique sirolimus formulation.
